Walvax Biotechnology has reportedly ended negotiations for a tie-up with GlaxoSmithKline because China regulators decided against allowing GSK to import its measles-mumps-rubella vaccine (MMR). The vaccine was the centerpiece of a JV that Walvax and GSK announced two years ago, and a manufacturing facility was completed one year later. It isn’t immediately clear what “ending negotiations” means for the fate of the facility. More details....

Stock Symbols: (SHE: 300142) (NYSE: GSK)

Share this with colleagues: